IV tenecteplase: A non-inferior alternative to alteplase?
IV tenecteplase: A non-inferior alternative to alteplase?
复制标题
静脉注射替奈普酶：阿替普酶的非劣质替代品？
DOI：
10.1016/j.medj.2022.07.006
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Sheth,KevinN
中科院分区：
文献类型：
--
作者：
Zubair,AdeelS;Sheth,KevinN
3小时内出现卒中的患者静脉溶栓的标准药物治疗是阿替普酶，一种组织纤溶酶原激活剂。Menon及其同事评估了替奈普酶（阿替普酶的改良版本）在发病4.5小时内出现的急性缺血性卒中患者中的非劣效性、疗效和安全性。
The standard medical therapy for intravenous thrombolysis in patients with stroke presenting within 3 h is alteplase, a tissue plasminogen activator. Menon and colleagues assessed the non-inferiority, efficacy, and safety of tenecteplase, a modified version of alteplase, in patients with acute ischemic stroke presenting within 4.5 h of onset.